ReviewCancer cell international2025
Diagnostic and therapeutic potential of exosomal circRNAs in cancer: decoding the circular code toward precision medicine.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exosomes and lung cancer: Biogenesis, pathogenic mechanisms, biomarkers, and therapeutic applications.The Journal of international medical research · 2026Review
- Exosome-mediated post-transcriptional oncogene regulation as a novel cancer therapeutic strategy.Discover oncology · 2026Review
- Review
- circ-UBR5 in hypoxia-induced exosomes may mediate lung adenocarcinoma metastasis via the targeting of HNRNPR.Translational lung cancer research · 2026Article
- Comprehensive landscape and future perspectives of exosomal circular RNAs in cardiovascular disease.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs), a unique class of non-coding RNAs, have gained attention due to their stable closed-loop structure and involvement in diverse cellular processes. Their remarkable stability and abundance in biological fluids, particularly when encapsulated within exosomes, make them highly promising candidates for clinical applications. This review offers a detailed insight into the growing field of exosomal circRNAs, starting with the fundamental principles of circRNA biogenesis and the selective mechanisms governing their sorting into exosomes. We explore the complex regulatory network controlled by circRNAs, highlighting their roles as microRNA (miRNA) sponges, interactors with RNA-binding proteins (RBPs), regulators of transcription and RNA stability, and even as templates for translating into novel peptides or proteins. We elucidate how these actions are mediated by exosomal circRNAs when delivered to recipient cells, influencing the behavior of target cells. The review critically evaluates the current and emerging methodologies for the detection, quantification, and functional analysis of exosomal circRNAs. We extensively discuss the clinical implications, highlighting the significant potential of exosomal circRNAs as non-invasive biomarkers for the diagnosis, prognosis, and monitoring of various diseases, with a particular focus on cancer. Furthermore, we explore their therapeutic landscape, including strategies for targeted delivery, their role in modulating drug resistance, and their intricate functional crosstalk with other non-coding RNAs in cancer progression. While recognizing the promising potential of exosomal circRNAs, we also address the existing technical challenges and highlight the future directions needed to leverage their diagnostic and therapeutic applications. Our review highlights the significance of interpreting the circular code of exosomal circRNAs as a vital step toward achieving the objectives of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.